MapLight Therapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 6 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2024 | Dec2024 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -19.81M | -21.88M | -29.98M | -29.95M | -80.91M | -61.20M |
| Share-based Compensation | 0.35M | 0.15M | 6.21M | 35.52M | 42.00M | |
| Cash from Operations | -21.49M | -31.79M | -46.83M | |||
| Depreciation, Depletion & Amortization | ||||||
| Amortizatization of Intangibles | 0.41M | 0.46M | 1.44M | |||
| Change in Working Capital | ||||||
| Change in Account Payables | -0.16M | 0.30M | 0.89M | |||
| Change in Accured Expenses | 1.21M | 2.61M | 1.12M | |||
| Other Working Capital Changes | 1.40M | 3.91M | 2.33M | |||
| Investing Activities | ||||||
| Capital Expenditures | 0.11M | 0.03M | 0.38M | |||
| Change in Acquisitions & Divestments | 32.50M | 6.50M | 24.00M | |||
| Cash from Investing Activities | 32.39M | -135.59M | -242.55M | |||
| Financing Activities | ||||||
| Other financing activities | 0.02M | 0.92M | 3.89M | |||
| Change in Capital Stock | ||||||
| Net Shares Issued and Repurchased | 2.95M | |||||
| Net Equity Issued and Repurchased | 200.00M | 200.00M | ||||
| Misc. | ||||||
| Cash from Financing Activities | 0.01M | 198.06M | 271.96M | |||
| Change in Cash | 10.91M | 30.68M | -17.42M | |||
| Free Cash Flow | -21.59M | -31.82M | -47.20M | |||
| Net Cash Flow | 10.91M | 30.68M | -17.42M |